Physician profile
Fadi E Saba
NPI 1588658348
$28,093.84
in general payments reported to CMS, 2019-2025
88 companies · $4,613 in 2025
The $4,613 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,507 · 2020: $6,467 · 2021: $3,633 · 2022: $4,676 · 2023: $1,646 · 2024: $1,552 · 2025: $4,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,084 · Consulting Fee: $2,610 · Travel and Lodging: $74.72 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,083.98 |
| Consulting Fee | $2,609.50 |
| Travel and Lodging | $74.72 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $8,488.16 | 2019-2025 | Airsupra, Andexxa, Farxiga |
| Merz North America, INC. | $5,084.16 | 2019-2023 | Xeomin |
| Astellas Pharma US INC | $3,780.03 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,031.76 | 2023-2025 | |
| Abbvie INC. | $941.55 | 2019-2025 | Vraylar, Linzess, Qulipta |
| Pfizer INC. | $449.68 | 2019-2025 | |
| Abbott Laboratories | $429.76 | 2019-2025 | Freestyle Libre 2, Mitraclip |
| Glaxosmithkline, LLC. | $366.44 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $331.87 | 2019-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $299.39 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $274.52 | 2019-2023 | Nayzilam, Briviact |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $271.86 | 2019-2025 | Xifaxan |
| Axonics, INC. | $247.52 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $246.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.92 | 2019-2024 |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $196.69 | 2019-2025 | Collagenase Santyl |
| Cipher Pharmaceuticals US LLC | $195.43 | 2025 | Natroba, Spinosad |
| Galderma Laboratories, L.P. | $195.17 | 2020-2023 | |
| Allergan, INC. | $192.16 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $180.68 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $175.62 | 2024 | Voquezna |
| Neurocrine Biosciences, INC. | $156.80 | 2022-2025 | Ingrezza, Ongentys |
| Janssen Pharmaceuticals, INC | $144.84 | 2022-2024 | Xarelto |
| Gilead Sciences, INC. | $141.66 | 2019-2025 | |
| Bard Peripheral Vascular, INC. | $141.50 | 2022 | |
| Amgen INC. | $139.12 | 2019-2024 | Repatha, Otezla, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.17 | 2025 | Caplyta |
| Cardinal Health 200 LLC | $114.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.52 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $106.35 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Insmed, INC. | $104.13 | 2020-2025 | Arikayce, Brinsupri |
| Dexcom, INC. | $81.30 | 2023-2025 | Dexcom G6 Transmitter |
| Lucid Diagnostics INC. | $60.19 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $54.82 | 2024 | Onpattro |
| Sanofi-Aventis U.S. LLC | $53.15 | 2019-2024 | |
| Boston Scientific Corporation | $52.12 | 2022-2024 | Watchman Access System |
| Scilex Pharmaceuticals INC. | $50.65 | 2019-2024 | |
| Medtronic Vascular, INC. | $50.11 | 2019 | |
| Coloplast Corp | $46.92 | 2024 | |
| Corcept Therapeutics | $45.08 | 2024 | Korlym |
| Mannkind Corporation | $42.50 | 2025 | |
| Acadia Pharmaceuticals INC | $41.65 | 2019-2021 | |
| Lundbeck LLC | $41.53 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $30.56 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $28.64 | 2023-2025 | Jardiance, Lyumjev, Baqsimi |
| Tonix Medicines, INC. | $27.21 | 2025 | Tonmya |
| Nestle Healthcare Nutrition INC. | $25.55 | 2023 | |
| Viiv Healthcare Company | $24.91 | 2023 | Dovato |
| Si-Bone, INC. | $24.90 | 2024 | |
| Xeris Pharmaceuticals, INC. | $24.27 | 2025 | Keveyis |
| Scpharmaceuticals INC. | $23.96 | 2025 | |
| Melinta Therapeutics, LLC | $23.49 | 2019 | |
| Corium, LLC | $23.24 | 2022 | |
| Ardelyx, INC. | $22.50 | 2025 | Ibsrela |
| Seqirus USA INC | $21.61 | 2025 | Fluad, Flucelvax |
| E.R. Squibb & Sons, L.L.C. | $20.70 | 2025 | Cobenfy |
| Eisai INC. | $19.85 | 2020 | |
| Hologic Sales and Service, LLC | $19.82 | 2025 | Aptima, Thinprep 2000 Processor |
| Angiodynamics, INC. | $19.60 | 2019 | |
| Greenwich Biosciences, INC. | $19.45 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $17.40 | 2025 | Uptravi |
| Lifescan, INC. | $17.04 | 2023 | |
| Alkermes, INC. | $16.90 | 2023 | Aristada, Lybalvi |
| Valeritas, INC. | $16.65 | 2019 | |
| Amarin Pharma, INC. | $16.41 | 2019 | |
| Shield Therapeutics INC | $15.02 | 2024 | |
| Renalytix Ai, INC. | $14.75 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Aimmune Therapeutics, INC. | $14.04 | 2024 | |
| Vivus LLC | $13.53 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.32 | 2024 | Nuzyra |
| Mylan Specialty L.P. | $13.27 | 2019 | |
| Sanofi Pasteur INC. | $12.49 | 2019 | |
| Inogen, INC. | $12.37 | 2022 | |
| Apyx Medical Corporation | $10.20 | 2019 | |
| Sumitomo Pharma America, INC. | $9.89 | 2023 | Gemtesa |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,548.90 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.